PFIZER INC

CIK 78003 · last filed 2024-08-05

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$29.45B

Companies

14

Total Filings

26

Lifetime Open-Market Net

$116.74M

Filer Profile

Reported Address
66 HUDSON BOULEVARD EAST
NEW YORK, NY 10001-2192
Phone
(212) 733-2323
State of Incorporation
DE
Formerly Known As
PFIZER INC (1994–2026)
Related Filers
ALBERT BOURLA — 346 joint filings, latest 2026-09-01
RADY A JOHNSON — 290 joint filings, latest 2025-01-03
JOHN D YOUNG — 193 joint filings, latest 2021-12-16
JENNIFER B. DAMICO — 137 joint filings, latest 2026-08-06
ANTHONY J MADDALUNA — 103 joint filings, latest 2017-02-07
IAN C READ — 88 joint filings, latest 2019-03-06
SHANTANU NARAYEN — 66 joint filings, latest 2026-06-30
DOUGLAS M LANKLER — 64 joint filings, latest 2026-03-05
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
PYXS 10%+ Owner 7,032,770 $3.27 $23.00M $20.00M 2 2023-03-23
Viatris Inc (VTRSV) Delisted 10%+ Owner 0 $0 1 2020-11-16
Cerevel Therapeutics Holdings, Inc. (CEREW) Delisted 10%+ Owner 27,349,211 $18.07 $494.20M $12.00M 1 2020-10-29
SpringWorks Therapeutics, Inc. (SWTX) Delisted 10%+ Owner 4,593,847 $46.99 $215.86M $1.80M 1 2019-09-19
Quince Therapeutics, Inc. (CRTX) Delisted 10%+ Owner 2,360,071 $1.95 $4.60M $2.55M 1 2019-05-14
ALLO 10%+ Owner 21,976,484 $1.76 $38.68M $1.00M 1 2018-10-17
RYTM 10%+ Owner 1,387,639 $102.20 $141.82M $680.0K 1 2017-10-10
SYNLOGIC, INC. (MIRN) Delisted 10%+ Owner 1,539,224 $5.00M 1 2015-10-07
Neurogene Inc. (AQXP) Delisted 10%+ Owner 1,135,634 -$3.88M 2 2015-08-12
FLXN 10%+ Owner 1,452,944 $24.58 $35.71M $0 1 2014-02-20
Eiger BioPharmaceuticals, Inc. (CLDN) Delisted 10%+ Owner 119,654 $1.82M 1 2014-02-06
ZTS Director 400,985,000 $72.86 $29.22B $0 2 2013-06-26
ICAGEN INC (ICGN) Delisted 10%+ Owner 6,393,776 $58.16M 3 2011-09-16
ENCYSIVE PHARMACEUTICALS INC (ENCY) Delisted 10%+ Owner 69,076,466 $17.61M 6 2008-04-15

Recent Filings · Page 3 of 3

26 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2008-04-15 ENCYSIVE PHARMACEUTICALS INC (ENCY) Delisted Buy (P) +1,387,911 $3.26M EDGAR
2008-04-11 ENCYSIVE PHARMACEUTICALS INC (ENCY) Delisted Buy (P) +223,422 $525.0K EDGAR
2008-04-09 ENCYSIVE PHARMACEUTICALS INC (ENCY) Delisted Buy (P) +2,232,827 $5.25M EDGAR
2008-04-07 ENCYSIVE PHARMACEUTICALS INC (ENCY) Delisted Buy (P) +2,385,833 $5.61M EDGAR
2008-04-07 ENCYSIVE PHARMACEUTICALS INC (ENCY) Delisted Buy (P) +1,081,178 $2.54M EDGAR
2008-04-03 ENCYSIVE PHARMACEUTICALS INC (ENCY) Delisted Buy (P) +181,909 $427.5K EDGAR
Showing 2126 of 26
Page 3 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.